meloxicam · Baudax · NDA 210583
Anjeso
Earliest generic entry, as listed
8 Mar 2039
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10881663, US 11458145. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10881663 | use U-3038 | 8 Mar 2039 |
| US 11458145 | use U-3318 | 8 Mar 2039 |
| US 10709713 | use U-2750 | 26 May 2030 |
| US 11253478 | product, use U-3318 | 26 May 2030 |
| US 9974746 | product | 26 May 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210583 · 001 · RLD · discontinued | solution, intravenous | 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 8 Mar 2039 |